Danske Bank’s BioXcel Therapeutics BTAI Stock Holding History

Danske Bank’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$5	–	1505
2025 Q2	$5	Hold	3	–	–	﹤0.01%	1476
2025 Q1	$6	Buy	+3	New	+$11	﹤0.01%	1328

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

Danske Bank's BTAI Position: Q3 2025 in Review

Danske Bank sold out of BioXcel Therapeutics (BTAI) in Q3 2025, closing a stake of 3 shares — an estimated $5 sold.

Danske Bank first reported a position in BTAI in Q1 2025 and held it in 2 quarters. The position peaked at $6 in Q1 2025. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

Danske Bank reported no remaining BioXcel Therapeutics position as of Q3 2025 after selling out during the quarter.
Danske Bank sold 3 BioXcel Therapeutics shares in Q3 2025, an estimated $5.
Danske Bank first reported a position in BioXcel Therapeutics in Q1 2025 and held it in 2 quarters.
Danske Bank's BioXcel Therapeutics position peaked at $6 in Q1 2025.
35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on Danske Bank's 13F filing for Q3 2025, filed 13 Nov 2025.